Pulmonary FibrosisGPNCT00258570
Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF)
An observational study of Pulmonary Fibrosis, run by University of Pittsburgh at 1 site in United States.
Trial summary
The purposes of this study are: to determine if there are specific genetic traits that might explain why patients have developed pulmonary fibrosis; to determine if specific genetic traits account for differing patterns of inflammation and scar tissue that has formed in the patient's lungs. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pulmonary Fibrosis
- How many people
- 2,000 participants
- Where
- 1 siteUnited States
- Study dates
- Jan 2003to Jul 2035
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patient population includes patients who have been diagnosed with a fibrotic interstitial lung disease who have been seen by a Simmons Center Physician.
Who may be able to join
- 18 years of age or older
- Diagnosis of pulmonary fibrosis confirmed by physical examination, pulmonary function testing, chest X-ray, and computed tomography (CT) scans.
- Adult patients who are seeking treatment at the Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease.
Who cannot join
- Under 18 years of age
- Non-fibrotic ILD
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
University of Pittsburgh
Pittsburgh, Pennsylvania, 15213
Michelle F MacPherson, MAT, 412-647-4537, macphersonmj@upmc.edu
Michelle Meyers, BSN, 412-692-2149, meyersma@upmc.edu
About this study
Official title: Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis
The purposes of this study are:
- to determine if there are specific genetic traits that might explain why patients have developed pulmonary fibrosis;
- to determine if specific genetic traits account for differing patterns of inflammation and scar tissue that has formed in the patient's lungs.
Read the detailed description
Idiopathic pulmonary fibrosis (IPF) is a disease of unknown etiology that is characterized by the insidious development of lung fibrosis ultimately leading to distortion of the lung architecture, respiratory failure, and death. IPF is one of several entities associated with pulmonary fibrosis called the idiopathic interstitial pneumonias (IIP). Based on the histopathologic features of the fibrotic process, it is possible to identify four distinct entities: usual interstitial pneumonia (UIP) (synonymous with IPF), nonspecific interstitial pneumonia (NSIP), desquamative interstitial pneumonia DIP), and acute interstitial pneumonia (AIP) (Hamman-Rich lung). Each type appears to have different clinical progression and a different response to anti-inflammatory therapy. Our overall objective is to elucidate the molecular pathogenesis of IPF (UIP) by identifying factors that determine host susceptibility to this disease. We hypothesize that patients who develop pulmonary fibrosis, have a genetic propensity to abnormal lung repair that leads to fibrosis after acute lung injury. We further hypothesize that these genetic susceptibilities may determine if the pathologic process in the lung after an insult becomes UIP, AIP, NSIP, or DIP. To explore these hypotheses we propose to characterize the genetic polymorphisms in candidate genes involved in inflammation, matrix turnover, fibroblast proliferation and differentiation, and epithelial cell proliferation; and to correlate this with indices of disease progression.
- Conditions
- Pulmonary Fibrosis
- Keywords
- "Lung[A04.400]"
- Medical subject headings
- Pulmonary Fibrosis
What is being measured
The primary outcome is the main question the study is designed to answer.
Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF)
Blood samples will be collected to validate in a large cohort the per- allele associations of prespecified SNPs with IPF case status adjusted for age , sex. smoking, and principal components of ancestry.
Measured: Sample collection will occur up to 5 years based on the current rate of sample collection.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Nov 2005 (estimated)
- Study startJan 2003
- Primary completionJul 2035 (estimated)
- Study completionJul 2035 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pulmonary FibrosisStudies of the same condition, open and under way.
- More trials run by University of PittsburghThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 2,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Pittsburgh
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Kevin F. Gibson, University of Pittsburgh
- Investigators
- Kevin F Gibson, MD, Principal investigator, University of Pittsburgh, Simmons Center for ILD
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00258570
- Sponsor's protocol ID
- STUDY20030223
- Acronym
- GP
- Status last verified
- Aug 2026
- First submitted
- 23 Nov 2005
- Last updated
- 31 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes